Immunohistochemical biomarkers in ameloblastomas
- PMID: 27571891
- DOI: 10.1080/00016357.2016.1224918
Immunohistochemical biomarkers in ameloblastomas
Abstract
Ameloblastoma is an aggressive odontogenic tumour, which is locally invasive and highly recurrent. Studies show that ameloblastoma is a benign odontogenic neoplasia, being relatively rare and occasionally presenting behaviour of malignant lesions. In addition to these particularities, the histological diagnosis of ameloblastoma can be challenging when the tumour shows high rates of mitosis, absence of nuclear pleomorphism, basilar hyperplasia and neural invasion. In order to help in the diagnosis, prognosis and treatment of this neoplasia, some immunohistochemical markers were shown to be associated with tumoural epithelium. The identification of these markers as well as of their association with clinical signs can be useful to elaborate more efficient treatment strategies and to control this pathology, including improvement of the quality of life of patients affected by this neoplasia. This article aims to review some markers associated with specific molecular pathways, bone remodelling, cell proliferation, apoptosis, cell signalling and tumour suppression.
Keywords: Ameloblastoma; immunohistochemistry; jaw; odontogenic tumours.
Similar articles
-
Overexpression of MDM2 protein in ameloblastomas as compared to adenomatoid odontogenic tumor.J Cancer Res Ther. 2012 Apr-Jun;8(2):232-7. doi: 10.4103/0973-1482.98976. J Cancer Res Ther. 2012. PMID: 22842367
-
p53 gene status and expression of p53, MDM2, and p14 proteins in ameloblastomas.J Oral Pathol Med. 2004 May;33(5):292-9. doi: 10.1111/j.0904-2512.2004.00044.x. J Oral Pathol Med. 2004. PMID: 15078490
-
Immunohistochemical expression of p53 and murine double minute 2 protein in odontogenic keratocyst versus variants of ameloblastoma.J Cancer Res Ther. 2020 Apr-Jun;16(3):521-529. doi: 10.4103/jcrt.JCRT_659_18. J Cancer Res Ther. 2020. PMID: 32719261
-
Differential Expression of Immunohistochemical Markers in Ameloblastoma & Ameloblastic Carcinoma: A Systematic Review and Meta-analysis of observational studies.F1000Res. 2024 May 31;13:557. doi: 10.12688/f1000research.149861.1. eCollection 2024. F1000Res. 2024. PMID: 39082057 Free PMC article.
-
Comprehensive insights into the understanding of hypoxia in ameloblastoma.Histol Histopathol. 2024 Aug;39(8):983-989. doi: 10.14670/HH-18-718. Epub 2024 Feb 1. Histol Histopathol. 2024. PMID: 38362601 Review.
Cited by
-
BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis.Cancers (Basel). 2022 Nov 14;14(22):5593. doi: 10.3390/cancers14225593. Cancers (Basel). 2022. PMID: 36428683 Free PMC article. Review.
-
Conventional Ameloblastoma. A Case Report with Microarray and Bioinformatic Analysis.Diagnostics (Basel). 2022 Dec 16;12(12):3190. doi: 10.3390/diagnostics12123190. Diagnostics (Basel). 2022. PMID: 36553196 Free PMC article.
-
New diagnostic molecular markers and biomarkers in odontogenic tumors.Mol Biol Rep. 2021 Apr;48(4):3617-3628. doi: 10.1007/s11033-021-06286-0. Epub 2021 Apr 6. Mol Biol Rep. 2021. PMID: 33822294 Free PMC article. Review.
-
Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.Clin Oral Investig. 2019 Feb;23(2):779-784. doi: 10.1007/s00784-018-2494-y. Epub 2018 May 31. Clin Oral Investig. 2019. PMID: 29855709
-
Low frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: An institutional study.J Oral Maxillofac Pathol. 2018 Sep-Dec;22(3):353-359. doi: 10.4103/jomfp.JOMFP_174_17. J Oral Maxillofac Pathol. 2018. PMID: 30651680 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources